SOURCE-LINKED STUDY SUMMARY
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- SURPASS-5 tested once-weekly tirzepatide versus placebo added to titrated insulin glargine over forty weeks.
- Who / model studied
- The randomized trial enrolled adults with type 2 diabetes inadequately controlled with daily insulin glargine, with or without metformin.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Adding tirzepatide improved glycemic control and reduced body weight versus placebo; diarrhea and nausea were more common.
- Limitations & context
- Premature treatment discontinuation was more frequent in each tirzepatide group than with placebo.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2022.0078